https://www.selleckchem.com/pr....oducts/zinc05007751.
21; 95% CI 1.42 to 3.44). Alteplase increased the risk of swelling (OR 1.69; 95% CI 1.11 to 2.57), with no difference between patients with and those without baseline HAS (p=0.49). In patients with baseline HAS, alteplase reduced the proportion with HAS at follow-up (OR 0.67; 95% CI 0.50 to 0.91), where HAS disappearance was associated with reduced risk of swelling (OR 0.25, 95% CI 0.14 to 0.47). Although alteplase was associated with increased risk of symptomatic infarct swelling in patients with or without baseline HAS, it was al
Curtir
Comentario
Compartilhar
